RxDoctor Payments Data

Marianna Golden, MD

Neurology · West Nyack, NYNPI 1538236278

Payments from drug & device makers

$15,629in general payments, 2019–2025

Across 840 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Lilly USA, LLC$910
  • UCB, Inc.$832
  • Kyowa Kirin, Inc.$634
  • SK Life Science, Inc.$524
  • Eisai Inc.$500
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$330%
  • Food & beverage$15,567100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)235$4,303
Lilly USA, LLC52$910
UCB, Inc.49$832
Kyowa Kirin, Inc.33$634
SK Life Science, Inc.25$524
Eisai Inc.22$500
Pfizer32$491
Amgen24$487
Novartis32$474
EMD Serono, Inc.19$449
Lundbeck LLC17$409
Sanofi17$349
Sumitomo Pharma America, Inc.16$330
Bristol Myers Squibb25$291
Acadia Pharmaceuticals Inc15$286
Amneal Pharmaceuticals LLC15$276
Adamas Pharmaceuticals, Inc.15$275
Grifols USA, LLC13$272
AstraZeneca(2 entities)11$229
Upsher-smith Laboratories LLC14$215
Biohaven Pharmaceuticals, Inc.14$211
Biogen9$172
Aucta Pharmaceuticals, Inc.11$167
Genentech USA, Inc.7$155
Sunovion Pharmaceuticals Inc.8$148
Currax Pharmaceuticals LLC10$134
Argenx US, Inc.5$132
Otsuka America Pharmaceutical, Inc.5$131
Abbott6$129
Assertio Therapeutics, Inc.7$122
Tanabe Pharma America, Inc.5$99
Supernus Pharmaceuticals, Inc.6$98
Mallinckrodt Enterprises LLC4$95
Biohaven Pharmaceutical Holding Company Ltd.5$94
Vertical Pharmaceuticals, LLC5$91
CSL Behring3$85
Axsome Therapeutics, Inc.3$79
Johnson & Johnson3$78
Neurocrine Biosciences, Inc.4$73
Mallinckrodt Hospital Products Inc.3$66
Boston Scientific2$55
Almatica Pharma LLC2$53
Catalyst Pharmaceuticals, Inc.2$48
Impel Pharmaceuticals Inc.2$48
Acorda Therapeutics, Inc3$48
TG Therapeutics, Inc.2$47
Avanir Pharmaceuticals, Inc.2$46
Arbor Pharmaceuticals, Inc.3$45
Alnylam Pharmaceuticals Inc.2$42
Medtronic2$38
ANI Pharmaceuticals, Inc.1$31
Promius Pharma LLC2$30
Corium, LLC1$27
Takeda Pharmaceuticals U.S.A., Inc.1$27
Teva Pharmaceuticals USA, Inc.2$24
Azurity Pharmaceuticals, Inc.1$24
Scilex Pharmaceuticals Inc.1$21
Xeris Pharmaceuticals, Inc.1$17
Neurelis, Inc.1$16
Aprecia Pharmaceuticals, LLC1$16

How this compares

$15,629 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$226,571
Medicare patients
574
Services billed
6,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant31$30,974
MysolinePrimidone13$24,873
Nurtec OdtRimegepant Sulfate13$22,212
VimpatLacosamide16$21,281
TopamaxTopiramate14$17,181
Levetiracetam228$11,213
Lacosamide45$11,185
Emgality PenGalcanezumab-Gnlm16$10,761
Rivastigmine17$5,032
Memantine Hcl ErMemantine Hcl21$4,782
Memantine Hcl133$4,648
Pregabalin100$3,826
Carbamazepine ErCarbamazepine19$3,687
Divalproex Sodium36$3,545
Donepezil Hcl311$3,087

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$4,303$30,97431 claims
PfizerNurtec Odt$491$22,21213 claims
UCB, Inc.Vimpat$832$21,28116 claims
Upsher-smith Laboratories LLCTopiramate$215$1,34950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.

Other neurology in West Nyack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →